Are these 2 FTSE 250 shares now unmissable buys after crashing 48%?

Harvey Jones is hunting for FTSE 250 bargains and reckons these two are ripe for a comeback after recent troubles. Dare he buy them both?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 250 contains plenty of great value stocks right now. These two have caught my eye after crashing hard. Should I snap them up before they recover?

Biotherapeutics company PureTech Health (LSE: PRTC) is popular among my fellow Fools. It’s not without risk though.

The PureTech share price has plunged 49.38% in the last three years. Over 12 months, it’s down 10.51%. The rate of descent has slowed, but not much.

PureTech is all about the future. It specialises in medicines related to the brain, gut, and immune system, and is currently pushing a pipeline of 28 therapeutics through US and EU regulatory processes.

PureTech offers outsized rewards

That involves spending bags of money on R&D today in the hope of making bags more when treatments make it to market. Inevitably, it’s a bumpy process.

Recent results make painful reading with a pre-tax loss in each the last three years. 2022 full-year revenues of $15.61m plunged to just $3.33m in 2023. Despite that, it ended the year with level cash, plus cash equivalents and short-term investments of $326m. The board says that gives it an operational runway into “at least 2027”.

CEO Bharatt Chowrira has talked up the group’s track record of clinical success, which he says is “six times the industry average”. Now he needs to make money from it.

PureTech recently treated investors to a $100m share buyback, using proceeds from the $14bn sale of the PureTech-founded Karuna Therapeutics to Bristol Myers Squibb. That’s a big buyback, given the group’s market cap of £393m. Not that it’s shifted the share price much.

The price could fly if it starts making money but it’s too risky for me to buy today. I’ll watch and wait to see what its future holds.

Assura is a dividend star

Real estate investment trust (REIT) Assura (LSE: AGR) is another Foolish favourite. It builds and manages a portfolio of community healthcare buildings such as GP surgeries, which it leases to the NHS. It’s been doing this for 20 years, now.

This should be a relatively solid investment, as rents are ultimately underpinned by local authorities. However, it’s been hit by volatile property values, swinging from a full-year profit of £155.8m in 2022 to a £119.2m loss in 2023. The culprit was the surge in interest rates following former PM Liz Truss’s mini-Budget meltdown in autumn 2022. 

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice.

The Assura share price has crashed 46.4% over three years and is down 5.5% over 12 months. It now looks decent value at 12.24 times earnings, but hardly dirt cheap.

Total revenues have been rising steadily year-on-year, despite the challenging economic environment. Net rental income climbed 9% to £138m in 2023. The pace slowed to 3.8% in 2024, though, lifting net income to £143.3m.

Assura’s balance sheet remains robust with undrawn facilities and cash of £235m, marginally down from £243m a year earlier. It could get a nice boost if interest rates fall and property prices rise.

The big attraction is the dividend, with a trailing blockbuster yield of 7.87%. Better still, the company increased shareholder payouts by 5.2% in May. That’s a brilliant income at a decent price. Plus potential share price growth too. I’ll buy it when I have the cash. And keep watching PureTech.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

Here are the best-performing S&P 500 stocks after the US election result

Jon Smith notes some of the largest gainers from the S&P 500 yesterday and explains how the election result has…

Read more »

Growth Shares

2 UK stocks knocking on the door of promotion to the FTSE 100

Jon Smith points out a couple of UK stocks that he feels could be ready for the big league based…

Read more »

Investing Articles

Rolls-Royce shares just fell 7%. Is it time to buy?

This investor in Rolls-Royce shares takes a look at the FTSE 100 engine maker's trading update to see what caused…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

What’s going on with the Auto Trader share price?

Paul Summers takes a closer look at why the Auto Trader share price has tumbled despite the company posting higher…

Read more »

Investing Articles

Legal & General shares look set to give me a mind-blowing 10.22% yield in 2026!

Harvey Jones is getting a brilliant second income from his Legal & General shares and expects even more to come.…

Read more »

Investing Articles

I’d consider this beaten-down FTSE 100 dividend stock to target a second income of £19,000

Our writer sees an opportunity to earn a substantial second income by investing in this UK insurance giant. Here’s his…

Read more »

Investing Articles

How cheap is the 72p Vodafone share price?

The Vodafone share price looks very cheap having fallen to a 72p price tag. But is it really the bargain…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Up 43% in a year and the IAG share price could keep on rising!

One of the FTSE 100’s highest-flying stocks still looks cheap on an earnings basis. Is this a brilliant buy for…

Read more »